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Abstract  
Graves' disease and Hashimoto's thyroiditis are autoimmune thyroid disorders with distinct pathological and histopathological features. The 
conversion from Hashimoto's thyroiditis to Graves' disease has been rarely reported throughout the world with no reports in the African race to our 
knowledge. We here report an African lady who was initially diagnosed with primary hypothyroidism following Hashimoto's disease but later 
became thyrotoxic due to Graves' disease. 
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Introduction 
 
There are few reports in the literature of hyperthyroidism after an 
initial period of hypothyroidism [1-4]. These have been mainly in 
Asian and Western populations. It is important to identify the rare 
patients who develop hyperthyroidism after initial treatment for 
hypothyroidism to enable prompt discontinuation of thyroxine and 
institution of appropriate treatment for hyperthyroidism. We found 
no reports in the English literature of hyperthyroidism following 
hypothyroidism in an African patient. We herein, report on a middle 
aged black South African female, who was initially diagnosed with 
hypothyroidism due to Hashimoto's thyroiditis but later developed 
Graves' disease after 5 years of thyroxine replacement. 
  
  
Patient and observation 
 
A 54-year-old black South African female from the Eastern Cape 
Province was initially diagnosed in 2011 with primary 
hypothyroidism secondary to Hashimoto's thyroiditis when she 
presented with progressive weight gain, constipation and cold 
intolerance. She had no goiter. Laboratory test results at diagnosis 
revealed extremely low thyroid hormone levels: serum free T4 of 
1.3 pmol/L (12-22) and free T3 of < 0.4 pmol/L (2.8-7.1). This was 
accompanied with markedly elevated TSH of 86.71 miu/L (0.27-4.2). 
Thyroid peroxidase antibody level was elevated at 153 iu/ml (0-35). 
She was subsequently started on thyroxine replacement and the 
dose was gradually increased to150 mcg daily. 
  
In June 2016, she presented with history of palpitations, heat 
intolerance, tremors, exertional dyspnoea and bilateral pitting 
oedema. She had sinus tachycardia of 135 beats per minute with 
elevated blood pressure of 150/105 mmHg. Thyroid function tests 
(TFT) at presentation in June 2016 showed markedly elevated free 
T4 (72.2 pmol/L) and free T3 (30.8 pmol/L) with suppressed TSH of 
< 0.01 miu/L. She was diagnosed with a thyrotoxic heart failure and 
thyroxine replacement was stopped. She also received furosemide 
40 mg BD, bisoprolol 5mg daily, enalapril 5 mg BD and was later 
commenced on carbimazole 20 mg daily when her thyrotoxicosis 
persisted. Subsequently Graves' disease was confirmed by the 
finding of elevated TSH receptor antibody levels of 6.83 u/L (< 
1.75). The TFT results in July 2016 revealed free T4 and free T3 of 
20.6 pmol/L and 6.4 pmol/L respectively with suppressed TSH < 
0.01 miu/L. 
  
Carbimazole was stopped in July 2018 when follow up biochemistry 
showed frank hypothyroidism: low serum free T4 of 10.1 pmol/L 
(12-22) and elevated TSH of 13.9 miu/L (0.27-4.2). She was 
biochemically euthyroid on follow up visits of September 2018: 
serum free T4 of 14.9 pmol/L (12-22) and TSH of 2.35 miu/L (0.27-
4.2) and February 2019: serum free T4 of 12.3 pmol/L (12-22) and 
TSH of 0.39 miu/L (0.27-4.2). She has neither been treated with 





Written informed consent for this case report was obtained from the 
patient. A copy of the written consent is available for review by the 





Our patient initially had clinical and laboratory features of 
hypothyroidism due to Hashimoto's thyroiditis. When she became 
thyrotoxic and presented in heart failure after 5 years of 150 mcg 
daily thyroxine replacement for hypothyroidism, the initial thinking 
was that of thyroxine induced thyrotoxic heart failure. However, 
with the finding of elevated serum TSH receptor antibody titers and 
persistent thyrotoxicosis despite withdrawal of thyroxine, her 
diagnosis was revised from hypothyroidism due to Hashimoto's to 
hyperthyroidism due to Graves' disease. Chronic hypothyroidism 
with inadequate thyroxine replacement can result in pituitary 
hyperplasia and eventual thyrotoxicosis secondary to an 
autonomous secretion of TSH [5]. This is however, unlikely in our 
patient as an elevated and not suppressed TSH would be expected. 
  
Although the transition from thyrotoxicosis to hypothyroidism is 
rare, it occurs in the setting of Hashitoxicosis where following 
thyroid follicular cells destruction an initial phase of thyrotoxicosis 
due to leakage of preformed thyroid hormones is followed by 
permanent hypothyroidism [6]. Thyrotoxicosis following 
hypothyroidism is also rare and is often described in Asian and 
western populations [1-4]. This scenario has been described 
predominantly in middle aged females [7]. It may occur up to 20 
years after an initial period of hypothyroidism [8]. Our case is 
similar to other reports in literature in being a middle-aged female, 
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the exception is that she is of black race and we have not found 
reports describing it in the black ethnicity in the English language 
literature. The factors that have been associated with the transition 
from hypothyroid Hashimoto's to Graves' disease include thyroxine 
treatment which may promote the elaboration of TSH receptor 
stimulating antibodies [1]. Treatment with immunomodulatory 
agents such as interferon and alemtuzumab have also been 
implicated in the switch from hypothyroidism to thyrotoxicosis 
[9, 10]. Our patient, however, neither received interferon nor 
alemtuzumab. She expectedly received thyroxine replacement for 
chronic primary hypothyroidism. 
  
In all reports of transition from thyrotoxicosis to hypothyroidism and 
vice versa, it has been in the setting of autoimmune thyroid disease. 
The postulated mechanism includes a switch from TSH receptor 
blocking to TSH receptor stimulating antibodies [11]. Indeed, 
circulating levels of TSH receptor inhibiting and stimulating 
antibodies have been reported in the same patient [12]. The clinical 
manifestation will be determined by which antibody predominates 
and this may vary with time with the same patient clinically 
manifesting as Hashimoto's thyroiditis or Graves' disease [13]. 
Alternating episodes of hypothyroidism and hyperthyroidism may be 
ultimately stopped with thyroidectomy or radioactive ablation of the 
thyroid [8, 12]. 
  
This case report is not without limitations; we did not test our 
patient for TSH receptor antibodies when she was diagnosed with 
hypothyroidism as it is not the standard of care. Our practice is to 
perform thyroid peroxidase antibody testing in primary 
hypothyroidism when Hashimoto's is suspected. Thyroid peroxidase 
antibody; which is positive in 90-95% of patients with Hashimoto's 
is the preferred test in autoimmune primary hypothyroidism 
[14, 15]. We also did not perform radionuclide imaging in our 
patient when she became thyrotoxic to demonstrate the expected 
pattern of diffusely increased uptake in Graves' disease because of 
the limited resources in our setting. We are aware that TSH receptor 
antibodies may be falsely positive in patients with thyrotoxicosis not 
due to Graves' disease [13]. However, we do not expect this to be 








In conclusion, our case extends the rare reports of Graves's disease 
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